Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE001 (USA) (Dr. Reyes)
· consented 2022-12-17
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 84); relationship: N
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-23 (study day 144); relationship: N
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-01-02 (study day 368); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-28 (study day 454); relationship: N
mild
assessed
2026-08-18
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-05-12 (study day 499); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-28 (study day 546); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.